Published online 2 September 2008
Haematologica, Vol 93, Issue 10, 1535-1543 doi:10.3324/haematol.13067
Copyright © 2008 by Ferrata Storti Foundation

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Griffioen, M. Articles by Heemskerk, M. H.M. Search for Related Content PubMed PubMed Citation Articles by Griffioen, M. Articles by Heemskerk, M. H.M.

Immunotherapy

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

Marieke Griffioen¹, H.M. Esther van Egmond¹, Helen Barnby-Porritt², Menno A.W.G. van der Hoorn¹, Renate S. Hagedoorn¹, Michel G.D. Kester¹, Nikolai Schwabe², Roel Willemze¹, J.H. Frederik Falkenburg¹, Mirjam H.M. Heemskerk¹

¹ Laboratory of Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands
² ProImmune Ltd., The Magdalen Centre, Oxford Science Park, Oxford, UK

Correspondence: Marieke Griffioen, Department of Hematology, C2-R, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail:m.griffioen{at}lumc.nl

Background: Donor lymphocyte infusion is an effective form of adoptive immunotherapy for hematologic malignancies after allogeneic stem cell transplantation. Graft-versus-host disease, however, often develops due to recognition of ubiquitously-expressed minor histocompatibility antigens. Transfer of T-cell receptors recognizing hematopoiesis-restricted minor histocompatibility antigens to virus-specific T cells may be a powerful anti-tumor therapy with a low risk of graft-versus-host disease. The purpose of this study was to develop an optimal T-cell receptors-encoding multi-cistronic retroviral vector and an efficient method for generating T-cell receptors-engineered virus-specific T cells.

Design and Methods: Retroviral vectors encoding the T-cell receptors for the hematopoiesis-restricted minor histocompatibility antigen HA-2 with and without selection markers were compared for T-cell receptors surface expression and HA-2-specific lysis. In addition, two different methods, i.e. peptide stimulation of CD8⁺ cells and Pro5® MHC pentamer-based isolation of antigen-specific T cells, were investigated for their efficiency to generate T-cell receptors-transduced virus-specific T cells.

Results: Bi-cistronic vectors without selection markers most efficiently mediated T-cell receptors surface expression and HA-2-specific lysis. Furthermore, both methods were useful for generating gene-modified cells, but the purity of virus-specific T cells was higher after pentamer isolation. Finally, the capacity of gene-modified cells to express the transgenic T-cell receptors at the cell surface markedly differed between virus-specific T cells and was correlated with lysis of relevant target cells.

Conclusions: Our data support T-cell receptors gene transfer to pentamer-isolated virus-specific T cells using bi-cistronic retroviral vectors and illustrate the relevance of selection of gene-modified T cells with appropriate transgenic T-cell receptors surface expression for clinical gene therapy.

Key words: allogeneic stem cell transplantation, immunotherapy, gene therapy, T cell receptor.

This article has been cited by other articles:

				A. N. Stumpf, E. D. van der Meijden, C. A. M. van Bergen, R. Willemze, J. H. F. Falkenburg, and M. Griffioen Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity Blood, October 22, 2009; 114(17): 3684 - 3692. [Abstract] [Full Text] [PDF]

				M. Griffioen, E. H.M. van Egmond, M. G.D. Kester, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy Haematologica, September 1, 2009; 94(9): 1316 - 1320. [Abstract] [Full Text] [PDF]